Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Feb;100(2):310-5.
doi: 10.1111/j.1349-7006.2008.01020.x.

Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer

Yoshinori Hirashima  1 , Yasuhide Yamada, Junichi Matsubara, Daisuke Takahari, Natsuko Okita, Atsuo Takashima, Ken Kato, Tetsuya Hamaguchi, Kuniaki Shirao, Yasuhiro Shimada, Hirokazu Taniguchi, Tadakazu Shimoda
Affiliations

Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer

Yoshinori Hirashima et al. Cancer Sci. 2009 Feb.

Abstract

Tumor angiogenesis is a multistep interactive process in which vascular endothelial growth factor (VEGF) and its receptors have a major role. However, the clinical significance of these molecules in gastric cancer (GC) remains unclear. Our study group comprised 86 patients who underwent gastrectomy and subsequently received chemotherapy for recurrent or residual tumor. Using immunohistochemical techniques, we analyzed the expression of VEGF receptors (VEGF-R) 1, 2, and 3. VEGF-R1 expression (defined as >5% staining) was found in the tumor cells of 65 tumors (76%) and in the stromal vessels of 36 tumors (42%). VEGF-R2 expression was found in tumor cells and stromal vessels of 0 and 46 tumors (0 and 53%), respectively, and VEGF-R3 expression was found in tumor cells and stromal vessels of 0 and 75 tumors (0 and 87%), respectively. Univariate analysis revealed that VEGF-R expression correlated with shorter survival (VEGF-R1 in stromal vessels, P = 0.001; VEGF-R2 in stromal vessels, P = 0.009; VEGF-R3 in stromal vessels, P = 0.005) and lower response to S-1 (VEGF-R1 in stromal vessels, P = 0.039). Multivariate analysis of potential prognostic factors showed that VEGF-R1 and VEGF-R2 in stromal vessels were independent predictors of poor outcome. Our data suggest that VEGF-R expression can be a predictor of unfavorable clinical outcome in GC. VEGF-R are promising candidates as therapeutic targets.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Typical examples of (a) CD34 staining, (b) D2‐40 staining, (c) CD31 staining, (d) factor VIII staining, and (e) negative controls. (a) Vascular endothelial growth factor receptor (VEGF‐R) 1 is mainly expressed in tumor cells, secondarily on stromal vessels. (b–d) VEGF‐R2 and VEGF‐R3 are mainly expressed on stromal vessels. Original magnification, ×200.
Figure 2
Figure 2
Impact of (a) vascular endothelial growth factor receptor (VEGF‐R) 1, (b) VEGF‐R2, and (c) VEGF‐R3 expression in stromal vessels on patient survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108. - PubMed
    1. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986; 46: 5629–32. - PubMed
    1. Brown LF, Berse B, Jackman RW et al . Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993; 53: 4727–35. - PubMed
    1. Brown LF, Berse B, Jackman RW et al . Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 86–91. - PubMed
    1. White JD, Hewett PW, Kosuge D et al . Vascular endothelial growth factor‐D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res 2002; 62: 1669–75. - PubMed

MeSH terms

Substances